<p>Section I: General Considerations<br>1. Epidemiology and Trend of Prognosis in Cancer Patients<br>2. Categories of Anticancer Treatments<br>3. Classification by Mechanisms of Cardiotoxicity<br>4. Cardiotoxicity of Oncologic Treatments: Is There a Uniform Definition?<br>5. The Impact of Radiotherapy</p> <p>Section II: Detrimental Effects of Anticancer Drugs and Radiotherapy on the Heart<br>6. Lessons From Preclinical Models<br>7. Genetic and Epigenetic Risk Factors<br>8. Changes of Myocardial Structure and Function<br>9. Alteration of Heart Valves<br>10. Pericardial Damage<br>11. Effects of Radiotherapy on Vessels and Coronary Arteries<br>12. Cardiac Conduction Disturbances</p> <p>Section III: Cardiovascular Complications of Cancer Treatments<br>13. Cardiac Rhythm Disturbances<br>14. Acute and Chronic Heart Failure<br>15. Coronary Artery Disease<br>16. Pericardial Effusion and Pericarditis<br>17. Radiation-Induced Carotid Atherosclerosis<br>18. Valvular Heart Disease<br>19. Atrial Fibrillation and Stroke in Cancer Patients</p> <p>Section IV: Imaging Evaluation of Cardiac Structure and Function in Cancer Patients<br>20. The Role of Echocardiography<br>21. The Role of Cardiovascular Magnetic Resonance (CMR)<br>22. Nuclear Medicine Imaging and Cardiotoxicity</p> <p>Section V: Detection of Cardiac Dysfunction and Predictors of Cardiotoxicity<br>23. Detection by Cardiac Imaging: LV Ejection Fraction, Diastolic Dysfunction, Tissue Doppler, and Speckle Tracking Echocardiography<br>24. The Role of Biomarkers: Troponins, BNP, MPO, and Other Biomarkers<br>25. Screening and Comprehensive Follow-Up Evaluation<br>26. Preoperative Assessment for Noncardiac Surgery</p> <p>Section VI: Cardiotoxicity in Childhood<br>27. Cardiotoxicity of Childhood Cancer Treatments</p> <p>Section VII: Management of Anticancer Drugs Related Cardiotoxicity<br>28. Nonpharmacologic Therapy<br>29. Beta-Blockers<br>30. Angiotensin-Converting Enzyme Inhibition<br>31. Diuretics<br>32. Antiarrhythmic Drugs<br>33. Anticoagulation in Cancer Patients<br>34. New Drugs: The Beneficial Effects of Ranolazine<br>35. Percutaneous Coronary Intervention and Cardiac Surgery in Cancer Patients<br>36. Focus on the Patient With Known Cardiac Disease<br>37. Multidisciplinary Approach to Cardiac Disease in Cancer Patients</p> <p>Section VIII: Future Research Priorities<br>38. Pharmacogenomics Screening<br>39. Cardiac Monitoring During Clinical Trials<br>40. Preventive Therapy<br>41. Cardiotoxicity: Future Research Directions</p>
